Innate Pharma (IPHA) Free Cash Flow (2019 - 2025)
Innate Pharma's (IPHA) quarterly Free Cash Flow came in at $162966.1 in Q4 2025, down 61.0% YoY from $417820.8 in Q4 2024, and down 61.0% on a QoQ basis from $417820.8 in Q4 2024.
Innate Pharma (IPHA) Free Cash Flow (2019 - 2025) Analysis & Trends
Innate Pharma (IPHA) has 7 years of Free Cash Flow data on file, last reported at $162966.1 in Q4 2025.
- Quarterly Free Cash Flow fell 61.0% year-over-year to $162966.1 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $885546.1 (down 19.75% YoY) and the FY2025 annual result came in at -$61.6 million, down 690.72% from the prior year.
- Free Cash Flow declined to $162966.1 in Q4 2025, from $417820.8 in the prior quarter.
- In the past five years, Free Cash Flow ranged from a high of $1.1 million in Q4 2021 to a low of $1067.1 in Q2 2022.
- A 5-year average of $327998.4 and a median of $304759.2 in 2024 frame the typical range for Free Cash Flow.
- Annual changes were most pronounced in 2022 — Free Cash Flow tumbled 98.59% — and 2024, when it jumped 9229.06%.
- Tracing IPHA's Free Cash Flow over 5 years: stood at $1.1 million in 2021, then slumped by 48.64% to $545832.3 in 2022, then slumped by 30.81% to $377654.9 in 2023, then grew by 10.64% to $417820.8 in 2024, then slumped by 61.0% to $162966.1 in 2025.
- The last three Free Cash Flow figures came in at $162966.1 (Q4 2025), $417820.8 (Q4 2024), and $304759.2 (Q2 2024), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.64 Bn | 130.78 Bn | 2.84 Bn | 1.01 Bn |
| 2 | Regeneron Pharmaceuticals | 85.89 Bn | 77.90 Bn | 3.93 Bn | 572.80 Mn |
| 3 | Argenx Se | 65.11 Bn | 59.93 Bn | 1.37 Bn | - |
| 4 | Moderna | 55.83 Bn | 50.69 Bn | 52.00 Mn | -563.00 Mn |
| 5 | BeOne Medicines | 42.01 Bn | 36.91 Bn | 1.53 Bn | 437.80 Mn |
| 6 | Alnylam Pharmaceuticals | 31.63 Bn | 28.32 Bn | 992.69 Mn | 292.04 Mn |
| 7 | BioNTech SE | 27.65 Bn | 9.26 Bn | 668.28 Mn | 433.84 Mn |
| 8 | Insmed | 27.46 Bn | 26.30 Bn | 358.27 Mn | -95.09 Mn |
| 9 | Royalty Pharma | 27.30 Bn | 26.47 Bn | - | 477.44 Mn |
| 10 | Innate Pharma | 199.79 Mn | 199.79 Mn | - | -61.25 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 162,966.09 |
| Dec 31, 2025 | 162,966.09 |
| Dec 31, 2024 | 417,820.80 |
| Dec 31, 2024 | 417,820.80 |
| Jun 30, 2024 | 304,759.18 |
| Jun 30, 2024 | 304,759.18 |
| Dec 31, 2023 | 377,654.91 |
| Dec 31, 2023 | 377,654.91 |
| Jun 30, 2023 | 3,266.77 |
| Jun 30, 2023 | 3,266.77 |
| Dec 31, 2022 | 545,832.34 |
| Dec 31, 2022 | 545,832.34 |
| Jun 30, 2022 | 1,067.06 |
| Jun 30, 2022 | 1,067.06 |
| Dec 31, 2021 | 1.06 Mn |
| Dec 31, 2021 | 1.06 Mn |
| Jun 30, 2021 | 75,869.10 |
| Jun 30, 2021 | 75,869.10 |
| Dec 31, 2020 | 1.08 Mn |
| Dec 31, 2020 | 1.08 Mn |